NIVOLUMAB + Catequentinib for sarcoma

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 1 trial. Early trial in people, checking safety. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 17 Oct 2019: Trial started, NCT04165330
  2. 15 Nov 2019: Trial registered, NCT04165330

The trials

NCT04165330: Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors

State
Under way
Phase
Phase 1 and Phase 2
People
56 planned
Started
17 Oct 2019
Primary completion
31 Dec 2027
Arms
AL3818 plus nivolumab
Results
None posted
  1. 17 Oct 2019: Trial started
  2. 15 Nov 2019: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 1 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.